STAT+: Mild Alzheimer's patients won't save Cassava Sciences

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

As we count down toward the December readout of Cassava Sciences’ simufilam Phase 3 clinical trial in Alzheimer’s disease, it’s a good time to correct one of the more egregious misconceptions regarding the handling of patient subgroup data that has been floating persistently around the internet.

I’m referring specifically to what Cassava can, and cannot, do with data from roughly 70% of 800 participants in the RETHINK-ALZ-52 study with mild Alzheimer’s. The remaining 30% of participants entered the study with moderate disease. 

Continue to STAT+ to read the full story…